Rafferty Asset Management
KALV

Rafferty Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Rafferty Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57,296
Closed -$1.15M – 1157
2026
Q1 		$1.15M Sell
57,296
-8,297
-13% -$134K ﹤0.01% 726
2025
Q4 		$1.06M Buy
65,593
+7,803
+14% +$103K ﹤0.01% 787
2025
Q3 		$704K Buy
57,790
+10,889
+23% +$150K ﹤0.01% 848
2025
Q2 		$530K Buy
46,901
+20,632
+79% +$252K ﹤0.01% 875
2025
Q1 		$303K Sell
26,269
-28,197
-52% -$288K ﹤0.01% 964
2024
Q4 		$461K Buy
54,466
+10,636
+24% +$110K ﹤0.01% 927
2024
Q3 		$508K Buy
+43,830
New +$551K ﹤0.01% 926
2022
Q2 		– Sell
-47,549
Closed -$701K – 1179
2022
Q1 		$701K Sell
47,549
-16,637
-26% -$239K ﹤0.01% 860
2021
Q4 		$849K Buy
64,186
+25,586
+66% +$407K ﹤0.01% 943
2021
Q3 		$674K Sell
38,600
-21,124
-35% -$428K ﹤0.01% 976
2021
Q2 		$1.43M Buy
59,724
+41,425
+226% +$1.08M 0.01% 777
2021
Q1 		$470K Buy
+18,299
New +$481K ﹤0.01% 981

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rafferty Asset Management's KALV Position: Q2 2026 in Review

Rafferty Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 57,296 shares — an estimated $1.15M sold.

Rafferty Asset Management first reported a position in KALV in Q1 2021 and held it in 12 quarters. The position peaked at $1.43M in Q2 2021. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Rafferty Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 57,296 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.15M.
  • Rafferty Asset Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 12 quarters.
  • Rafferty Asset Management's KalVista Pharmaceuticals position peaked at $1.43M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.